



British Columbia, *Naturally.*

BritishColumbia.ca

A leading research and development hub **at the forefront of innovation**

British Columbia (B.C.), Canada is a leading centre for scientific innovation and has a thriving life sciences industry. The province is the home to the fastest growing life sciences sector in Canada with respect to the number of businesses (+26.5% from 2018 to 2021).


British Columbia offers a highly skilled workforce, a prime location and a high quality of life. While scientific innovation is taking off in B.C., more companies with valuations over \$1 billion have come out of the province in the past year than anywhere else in Canada. B.C. has an ideal environment for investment and partnership opportunities in the life sciences.

B.C.'s internationally recognized research hospitals and universities partner with world class research institutions and research centers creating a dynamic, collaborative network for researchers. British Columbia has world-class scientists supported by one of the best health care systems in the world and international investors such as Glaxo Smith-Kline and Pfizer.



British Columbia's life sciences advantages

British Columbia's **prime location, outstanding talent** and **strong business climate** create an excellent environment for life sciences companies.



Industry Profile

British Columbia's diverse ecosystem is a leader in the research and development of new therapies and products. Key areas where British Columbia is producing world-leading products and services include HIV-AIDS, oncology, antibodies, precision medicine, nano-medicine, messenger ribonucleic acid (mRNA) vaccine technologies, lipid nanoparticles and genomics. Employment in the sector has grown 23.3% since 2018, including a growth of 10.4% in 2021 alone, making the life sciences sector one of the fastest growing sectors in B.C. In 2021, the province exported approximately \$650 million in life sciences goods and services to international destinations.

RESEARCH, TESTING AND MEDICAL LABORATORIES

British Columbia's life sciences industry demonstrates a particular strength in R&D, with companies focused on innovation and the development of new technologies. The research, testing and medical laboratories sector makes up the majority of British Columbia's life sciences sector at 68%, and this industry group experienced 26.5% growth between 2018 to 2021 — the fastest in Canada over that time period. This industry group accounts for the majority of B.C.'s life sciences employment, with 10,231 jobs or 54% of the total employment for the sector in 2021 while its contribution to B.C.'s GDP was \$1.1 billion.

MEDICAL DEVICES AND EQUIPMENT

British Columbia's medical devices and equipment industry group is launching pioneering products that benefit patients while delivering opportunity to investors. Whether it's the handheld diagnostic ultrasound imaging systems of Clarius Mobile Health, or the rapid on-site diagnostic tests, British Columbia's medical device companies have a history of successful innovation. StarFish Medical, based out of Saanich, is Canada's largest full-service medical device design, development and contract manufacturing company.

DRUG AND PHARMACEUTICALS

Job growth was the fastest in the drugs and pharmaceuticals industry group, adding 33% or 1,244 jobs from 2018 to 2021. Most revenue for the life science sector is attributed to the drugs and pharmaceuticals industry group (\$4.4 billion), and more specifically to wholesalers (\$3.3 billion or 46%) of the life sciences sector revenue.

HOME GROWN SUCCESSSES

British Columbia's biopharmaceutical and biomanufacturing companies are global leaders in developing solutions for patients worldwide. For example, STEMCELL Technologies is Canada's largest biotech company which develops cell culture media, cell separation systems, instruments and other reagents for use in life sciences research across basic and translational research continuums. British Columbia's medical technology sector is developing advanced mobile digital solutions including big data platforms, health applications and other solutions for a more connected health care ecosystem. For example, RxPx designed a platform to improve health outcomes and improve the patient experience; while PHEMI developed big data technologies which help organizations in health care sectors extract the most value possible from their data.



Abcellera

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com

COMPANY REPRESENTATIVES:

Michael Bayewitch, Vice President, Out-Licensing



Acuitas Therapeutics Inc.

Acuitas Therapeutics, Inc. is a Vancouver-based company focused on developing and optimizing lipid nanoparticle (LNP) delivery systems for nucleic acid-based therapeutics. They collaborate with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines.

Acuitas' clinically validated LNP technology has had a profound global impact — most notably enabling the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. Their technology also enables ONPATRO® by Alnylam, the first approved RNAi therapeutic for treating an otherwise rare and fatal disease. More recently, Acuitas' LNP technology has delivered other groundbreaking firsts: the first in-human proof of concept for genome base editing and the first personalized CRISPR therapy.

Today, Acuitas is advancing next-generation LNP. This includes targeted LNP for extrahepatic and in vivo CAR-T cell therapies, epigenetic medicines to modulate gene expression without altering DNA, multivalent vaccines for infectious diseases, as well as oncology vaccines, including personalized cancer vaccines.

COMPANY REPRESENTATIVES:

Miranda Lam, K.C., President & Chief Legal Officer
mlam@acuitastx.com



Applied Biological Materials Inc.

After more than 20 years of successful and profitable operations, Applied Biological Materials Inc. (abm) is emerging as a global leader in the cell biology space. Our growth is anchored by the development of the world's largest library of immortalized human and pet cell lines—comprising approximately 700 unique cell types. This extensive collection represents a highly defensible strategic asset that few, if any, global competitors can replicate. While technologies can be duplicated quickly, building such a biological library requires decades of sustained effort, giving abm a strong and enduring competitive advantage.

Their unique resources include functional mast cells, paired frontal and occipital dermal papilla cell lines, and the most comprehensive collection of pre-adipocytes from normal, obesity, and diabetic conditions. These assets have supported numerous biotechnology companies over the years and will continue to do so well into the future. Looking ahead, abm will invest heavily in organoid model development—leveraging both the existing cell line inventory and patient-derived tissues—to further support their customers in therapeutic research and development in the years to come.

In addition to unmatched cell biology products and services, abm is a world leader in:

- Recombinant lentiviral, AAV, and adenoviral vectors
- CRISPR-related gene knockout technologies
- Stable cell lines for gene overexpression
- Diagnostic PCR enzymes
- IHC primary antibodies for precision diagnostics

With the combination of unique biological assets, cutting-edge technology platforms, and decades of expertise, abm is positioned to drive innovation and deliver value to life science researchers worldwide.

COMPANY REPRESENTATIVES:

Peter Li, Ph.D. CEO



Bold Therapeutics

Vancouver-based Bold Therapeutics Inc. is a clinical-stage biopharmaceutical company and the world leader in the development of novel metallotherapeutics. At the 2024 ASCO Annual Meeting, Bold Therapeutics announced compelling Phase 2 data for its lead product BOLD-100 in the treatment of colorectal, biliary tract and gastric cancers showing significant improvements in both efficacy and safety over existing approved therapies.

COMPANY REPRESENTATIVES:

Russell McAllister, Chief Executive Officer
rm@bold-therapeutics.com

Company Profiles



DCx Biotherapeutics

DCx Biotherapeutics is developing next generation Precision Drug Conjugates (PDCs). Their vision is to develop a first-in-class pipeline of PDCs that are more efficacious and significantly less toxic than traditional antimitotic or topoisomerase inhibiting ADCs.

COMPANY REPRESENTATIVES:

David Poon, Co-Founder
dpoon@dcxbio.com



Eupraxia

Eupraxia is a publicly listed (TSX: EPRX) (NASDAQ: EPRX) clinical-stage biotechnology company headquartered in Victoria, BC, Canada. The company focuses on the development of new applications for existing products using its highly differentiated Diffosphere™ delivery technology that provides for up to 6 to 12 months release of locally delivered drug with a low initial Cmax. Eupraxia's products have the potential to address therapeutic areas with high unmet medical need, providing targeted, long-lasting treatment with improved pharmacokinetics and safety.

COMPANY REPRESENTATIVES:

Paul Brennan, Chief Business Officer
pbrennan@eupraxiapharma.com



Eyam

Eyam Vaccines and Immunotherapeutics is dedicated to transforming healthcare through cutting-edge biotech platforms. The Jennerator, an AI/ML-driven system, accelerates vaccine design by reducing time and cost while improving efficacy compared to traditional mRNA vaccines. The Gemini platform delivers self-amplifying nucleic acids as DNA or RNA without lipid nanoparticles (LNPs), offering long-term stability, flexibility, and scalability. Both platforms enhance manufacturing efficiency and payload stability, positioning Eyam at the forefront of next-generation, scalable healthcare solutions.

COMPANY REPRESENTATIVES:

Dr Pamela Housh, Senior Director of Business Development,
Eyam Therapeutics
phoush@eyamhealth.com



HtuO Biosciences

HTuO Biosciences is a deep-tech company that works at the interface of physics, chemistry, and computer programming to develop advanced computational drug discovery methods. The core technology uses a unique physics-based model to accurately represent the behaviours of atoms and molecules that better mimics the natural world and does not rely on training data. HTuO aims to leverage the core software AtomForge to transform drug design and expedite drug discovery, particularly for challenging-to-target proteins.



COMPANY REPRESENTATIVES:

Mr. Jacek Mis, Director of Business Development
jacek@htuo.bio



Integrated Nanotherapeutics

Integrated Nanotherapeutics (INT) is a preclinical-stage biotech company based in Vancouver, Canada, advancing first-in-class immune tolerance therapeutics for autoimmune diseases. The company has developed a differentiated multi-cargo lipid nanoparticle (LNP) platform capable of co-delivering multiple drug modalities within a single particle. INT's lead approach combines mRNA encoding disease-relevant autoantigen(s) with small-molecule immunomodulator(s) in one LNP to reprogram immune responses and induce durable, antigen-specific immune tolerance. This unique strategy enables targeted immune resetting without generalized immunosuppression.

INT is advancing a pipeline of tolerogenic therapies, with its lead program in type 1 diabetes supported by strong preclinical efficacy data demonstrating induction of regulatory T cells and disease remission in animal models. Additional applications of the platform are under evaluation in other autoimmune and immune-mediated conditions. To accelerate development, INT is raising a USD 30 million Series A financing to complete a Phase 1b clinical trial for the type 1 diabetes asset and to conduct IND-enabling studies for a second pipeline candidate.

COMPANY REPRESENTATIVES:

Chris Tam, Co-Founder & CEO
christam@integratedntx.com



Invest Vancouver

Invest Vancouver is Metro Vancouver's regional economic development service. By attracting strategic investment in key export-oriented industries, conducting research and policy analysis, and fostering collaboration on a local, national, and global scale, Invest Vancouver is facilitating the creation of high-quality jobs to achieve a resilient regional economy that delivers prosperity for all residents of the Metro Vancouver region. Working closely with leaders across all levels of government in the region and beyond, Invest Vancouver is addressing regional concerns to increase economic resilience, strengthening strategic export-oriented industries, attracting world-class companies, and laying the foundation for a region where every resident can thrive in today's rapidly evolving global economy.

COMPANY REPRESENTATIVES:

Jackie Griffiths, President
JGriffiths@investvancouver.ca



Kapoose Creek Bio

Kapoose Creek Bio is using the power of AI to revolutionize the discovery of medicines from nature. The firm has two exciting leads with remarkable potency in optimization for CNS indications, including Alzheimer's Disease and Major Depressive Disorder.

COMPANY REPRESENTATIVES:

Geordie Stewart, PhD MBA, Chief Growth Officer
geordie@kapoosecreek.com




Life Sciences BC

Life Sciences BC is a not-for-profit, non-government industry association that supports and represents British Columbia's life sciences community through numerous local, national, and international initiatives. We nurture economic development in the province through leadership, facilitation of investment and partnering, advocacy, and promotion of our world-class life sciences sector.

COMPANY REPRESENTATIVES:

Wendy Hurlburt, President & CEO
Whurlburt@lifesciencesbc.ca



Reverb Therapeutics

Reverb Therapeutics is advancing its Amplifier platform: a novel approach for cancer treatment, promoting targeted immune activation while limiting toxicity.

COMPANY REPRESENTATIVES:

David de Graff, Founder & CEO, Reverb Therapeutics
david@reverbtx.com

RxPx

RxPx is a technology platform that helps leading life sciences and pharmaceutical companies support patient safety and adherence requirements for complex and specialty therapies and trials in over 100+ countries. The RxPx Clinical AI Buddy is an intelligent conversational companion that provides personalized, 24/7 support to clinical trial participants. Built on advanced AI technologies in a privacy and regulatory compliant environment, this solution helps diversify patient recruitment and support, reduce operational overhead, and enhance patient physical and behavioural tracking throughout the entire clinical trial

journey. The RxPx platform includes a full trial toolkit, digital consent, screening, scheduling, and eCOA/ ePRO, plus secure real-world data capture across mobile and emerging interfaces. A secure data layer enables compliant, anonymized exchange with EMRs, labs, and pharmacies, and a flexible low-code API accelerates partner integrations.

COMPANY REPRESENTATIVES:

Caoimhe Vallely-Gilroy, Vice-President, Clinical Trial Solutions
Caoimhe@curatio.me



Sustained Therapeutics

Sustained Therapeutics is a clinical-stage company developing a patent-protected sustained-release drug delivery platform for localized delivery of approved drugs serving large unmet medical needs with significant market potential.

Its lead product (ST-01) is a non-opioid medication for the treatment of chronic, neuropathic and post-surgical pain. A phase I study has been successfully completed, and two phase II studies are underway, one in acute post-operative pain and one in chronic pain.

A successful interim review of data from the Phase II chronic pain trial has been carried out, with promising results. This review covered data at the trial's 80% completion point (50 of 63 patients treated). The study is now fully enrolled, and completion is anticipated in Q4 2025. Commencement of a Phase III trial in chronic pain is planned for 2026.

A second product (ST-02) is in a pivotal Phase II/III study. This product provides sustained release of chemotherapy medication in an orphan indication, Upper Tract Urothelial Carcinoma. The company believes that this product has potential application in other types of cancer, including bladder cancer.

The company has a strong management team with many years experience in the life sciences industry and in the development and launch of pharmaceutical products.

COMPANY REPRESENTATIVES:

Karen von Zitzewitz
kvonzitzewitz@sustainedtx.com



Tulevik

Tulevik is a life sciences advisory and consulting firm identifying transformative growth opportunities and partnerships powered by experience, analytics, and relationships. Tulevik provides next-generation search and evaluation services, curated M&A support services and innovative start-up and founder services. Their over 40 years of combined industry experience and partner network help Tulevik oversee acquisitions and divestment opportunities, contract outsourcing, valuations, and market entry strategy from search and evaluation to pre-transaction and transaction support.

COMPANY REPRESENTATIVES:

Kiirsten Suurkask, Founder
kiirsten@tulevik.bio



VARIATIONAL AI

Variational AI

Variational AI rapidly delivers novel, potent, and selective small molecule leads and optimized leads for biopharma customers that would not be discovered using status quo computational and medicinal chemistry methods. Founded in 2019 by leading AI/ML researchers and chemists, Variational AI is trusted by leading biopharmas such as Merck(MSD), Rakovina, and others. The Enki platform has a 56% hit rate of generating sub-uM novel compounds with selectivity and requires no additional data. Learn more at www.variational.ai

COMPANY REPRESENTATIVES:

Peter Guzzo, Vice President Drug Discovery
guzzo@variational.ai

Valentin Beuchillot, Senior Manager, Business Development
valentin@variational.ai



VoxCell BioInnovation



VoxCell BioInnovation

VoxCell is bioprinting cancer tissue models to be used as screening platforms for oncology drugs. Their tissue models contain an artificial vasculature, more closely mimicking the drug delivery inside of the human body. VoxCell is offering a service model, in which drug candidates are screened in-house and an efficacy data package is provided to the customer. Their goal is to revolutionize the way preclinical testing is done by offering a platform that can predict drug efficacy and improve drug development outcomes. Their mission is to allow the promising drugs to hit the market sooner, into the hands of people who need them.

COMPANY REPRESENTATIVES:

Karolina Valente, CEO
kvalente@voxcellbio.com

Graeme McLean, Director of Business Development
gmclean@voxcellbio.com



Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology-focused therapies to address areas of high unmet medical need.

COMPANY REPRESENTATIVES:

John Holyoake, VP Business Development
jholyoake@xenon-pharma.com

British Columbia, *Naturally.*



Trade and Invest British Columbia (European Representative Office)

Laetitia MacDougall
Investment & Trade Specialist – Europe

Phone: +44 7919 104515
lmacdougall@britishcolumbia.ca



BritishColumbia.ca